RecruitingNCT04839003
A Registry of AL Amyloidosis (ReAL)
A Registry to Investigate Real-world Natural History, Impact of Therapies and Patterns of Progression of AL Amyloidosis (ReAL)
Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
Enrollment
5,000 participants
Start Date
Feb 27, 2020
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this protocol is to generate a large registry of patients with AL amyloidosis.
Eligibility
Min Age: 18 YearsMax Age: 99 Years
Inclusion Criteria5
- diagnosis of systemic AL amyloidosis;
- treatment-naïve (pre-treatment data collected at participating center available for retrospective part);
- age ≥18 years;
- ability to understand and willingness to sign an informed consent (patients who already sign informed consent for clinical data to be used in retrospective analyses will be accepted);
- planned (or ongoing) follow-up at participating center.
Exclusion Criteria2
- non-AL amyloidosis;
- previous treatment for AL amyloidosis.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04839003
Related Trials
A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
NCT0664969510 locations
Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
NCT063831434 locations
A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)
NCT062059536 locations
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
NCT058986462 locations
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
NCT014082251 location